Table S1. Risk factors with Fibrosis-4 score for mortality in patients with COVID-19 receiving respiratory support

Variable	Univariate	Multivariate analysis	
	P value*	*P* value*	Hazard ratio (95% CI)
Male (yes/no)	0.143		
Comorbidities (yes/no)			
Hypertension	0.392		
Diabetes	0.001	0.008	1.998 (1.202-3.321)
Chronic obstructive pulmonary disease	0.087		
Chronic kidney disease	0.841		
Chronic liver disease	0.226		
ACE inhibitor/ARB use (yes/no)	0.871		
Lymphocyte count, $\times 10^3$/uL	<0.001	0.003	0.999 (0.998-1.000)
C-reactive protein, mg/L	0.584		
Total bilirubin, mg/dL	0.831		
Alkaline phosphatase, U/L	0.725		
Gamma glutamyl transferase, U/L	0.263		
Serum albumin, g/dL	0.773		
Prothrombin time, INR	0.444		
Estimated glomerular filtration rate, mL/min/1.73 ㎡	0.002		
SIRS on admission (yes/no)	<0.001		
Fibrosis-4 score	<0.001	<0.001	1.115 (1.069-1.163)

*Calculated by Cox proportional hazards regression test

ACE, angiotensin converting enzyme; ARB, angiotensin II receptor blocker; INR, international normalized ratio, SIRS, systemic inflammatory response syndrome.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Table S2. Adjusted hazard ratio of high Fibrosis-4 index for mortality in patients with COVID-19 receiving respiratory support

|	Death	
	HR (95% CI)	*P*-value
High Fibrosis-4 index (≥ 4.95) (yes vs. no)		
Unadjusted	3.93 (2.44-6.33)	<0.001
Model 1	3.01 (1.84-4.93)	<0.001
Model 2	3.02 (1.84-4.96)	<0.001
Model 3	2.80 (1.64-4.65)	<0.001

HR, hazard ratio; CI, confidential interval

Model 1 was adjusted for age, gender.

Model 2 was adjusted for chronic liver disease, diabetes, hypertension, chronic kidney disease, and chronic obstructive pulmonary disease inclusive of model 1.

Model 3 was adjusted for lymphocyte count, C-reactive protein, and presence of systemic inflammatory response syndrome inclusive of model 2.

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Figure S1. Survival of the patients with COVID-19 receiving respiratory support as the number of risk factors

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Figure S2. Survival of the entire group of patients with COVID-19 as the number of risk factors

Supplemental material

BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance placed on this supplemental material which has been supplied by the author(s)

BMJ Open

Number at risk

	0	10	20	30	40	50
< 2 risk factor	787	684	448	198	66	11
≥2 risk factor	218	190	135	65	30	1

Number at risk

	0	10	20	30	40	50
< 2 risk factor	973	849	562	250	89	12
≥2 risk factor	32	25	21	13	7	0